Furthermore, a recent study has revealed Gab1 not only as a convergence point between c-MET and EGFR pathways, but also suggests that Gab1 cooperates with MET amplification in lung cancer cells, which have become resistant towards the EGFR inhibitor gefitinib [204]. Here, GAB1 is linked to lung cancer.